Secukinumab: a Review of the Anti-IL-17A Biologic for the Treatment of Psoriasis

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2018 Jan 19

PMID 29344327

Citations 73

Authors

Jillian Frieder

Dario Kivelevitch

Alan Menter

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a systemic inflammatory disease associated with numerous comorbidities and a profound impact on patients' quality of life. While its complex immune pathogenesis is still not fully delineated, current evidence supports a fundamental role of the T-helper-17 (TH-17) pathway and its related interleukin-17 (IL-17) cytokine. Thus, new antipsoriatic therapies have been developed to block this key cytokine and its downstream effects. Secukinumab is a fully humanized, monoclonal anti-IL-17A antibody, and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis. It has also been approved for the treatment of active psoriatic arthritis and ankylosing spondylitis. Its clinical efficacy in plaque psoriasis has been well demonstrated in numerous phase II and III clinical trials. In addition, it has shown superiority in clinical trials to current biologic agents including etanercept and ustekinumab, with a safe adverse event profile. In correlation with excellent skin improvements, secukinumab is also associated with significant improvements in health-related quality of life measures. Thus, secukinumab offers the potential for equal, or improved, therapeutic effects compared with other biologics, and is a valuable addition to our current antipsoriatic armamentarium.

Citing Articles

"The Ameliorative Effect of Interleukin-17A Neutralization on Doxorubicin-Induced Cardiotoxicity by Modulating the NF-κB/NLRP3/Caspase-1/IL-1β Signaling Pathway in Rats".

Hassen M, Mousa N, Radwan S, Gabre R Inflammation. 2025; .

PMID: 40064794 DOI: 10.1007/s10753-024-02187-z.

FDA-Approved Secukinumab Alleviates Glial Activation and Immune Cell Infiltration in MPTP-Induced Mouse Model of Parkinson's Disease.

Li Q, Han X, Dong M, Bai L, Zhang W, Liu W Inflammation. 2025; .

PMID: 40011292 DOI: 10.1007/s10753-025-02267-8.

Telitacicept for systemic lupus erythematosus with post‑surgical papillary thyroid carcinoma: A case report.

Tan J, Huang H, Tan L, Li B Biomed Rep. 2025; 22(3):48.

PMID: 39882332 PMC: 11775643. DOI: 10.3892/br.2025.1926.

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing.

Rodriguez-Fernandez K, Zarzoso-Foj J, Saez-Bello M, Mateu-Puchades A, Martorell-Calatayud A, Merino-Sanjuan M Pharmaceutics. 2025; 16(12.

PMID: 39771555 PMC: 11678170. DOI: 10.3390/pharmaceutics16121576.

IL-17 Monoclonal Antibody Related HPV Exacerbation: A Case Report.

Kucukhemek F, Aypek Y, Ogut B, Adisen E Indian J Dermatol. 2024; 69(6):487.

PMID: 39678756 PMC: 11642462. DOI: 10.4103/ijd.ijd_390_24.

References

Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View

Ohtsuki M, Morita A, Igarashi A, Imafuku S, Tada Y, Fujita H . Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch. J Dermatol. 2017; 44(10):1105-1111. PMC: 5655923. DOI: 10.1111/1346-8138.13911. View

van de Kerkhof P, Griffiths C, Reich K, Leonardi C, Blauvelt A, Tsai T . Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016; 75(1):83-98.e4. DOI: 10.1016/j.jaad.2016.03.024. View

Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E . Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012; 366(13):1190-9. DOI: 10.1056/NEJMoa1109997. View

Kavanaugh A, McInnes I, Mease P, Hall S, Chinoy H, Kivitz A . Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. J Rheumatol. 2016; 43(9):1713-7. DOI: 10.3899/jrheum.160275. View

Langley R, Elewski B, Lebwohl M, Reich K, Griffiths C, Papp K . Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014; 371(4):326-38. DOI: 10.1056/NEJMoa1314258. View

Kirby B, Richards H, Mason D, Fortune D, Main C, Griffiths C . Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2007; 158(1):138-40. DOI: 10.1111/j.1365-2133.2007.08299.x. View

Blauvelt A, Reich K, Warren R, Szepietowski J, Sigurgeirsson B, Tyring S . Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. Br J Dermatol. 2017; 177(3):879-881. DOI: 10.1111/bjd.15656. View

Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A . Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol. 2014; 41(12):1039-46. DOI: 10.1111/1346-8138.12668. View

10.

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

11.

Yilmaz S, Cicek N, Coskun M, Yegin O, Alpsoy E . Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012; 304(6):465-9. DOI: 10.1007/s00403-012-1229-1. View

12.

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

13.

Callis Duffin K, Yeung H, Takeshita J, Krueger G, Robertson A, Troxel A . Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2013; 170(3):672-680. PMC: 4302409. DOI: 10.1111/bjd.12745. View

14.

Di Cesare A, Di Meglio P, Nestle F . The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009; 129(6):1339-50. DOI: 10.1038/jid.2009.59. View

15.

Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A . Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2016; 76(1):70-80. DOI: 10.1016/j.jaad.2016.07.058. View

16.

Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D . Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2015; 30(4):645-9. PMC: 4814339. DOI: 10.1111/jdv.13478. View

17.

Papp K, Langley R, Sigurgeirsson B, Abe M, Baker D, Konno P . Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol. 2012; 168(2):412-21. DOI: 10.1111/bjd.12110. View

18.

Xiong H, Gu J, He Z, Chen W, Zhang X, Wang J . Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015; 8(3):3156-72. PMC: 4443039. View

19.

Bissonnette R, Luger T, Thaci D, Toth D, Messina I, You R . Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol. 2017; 177(4):1033-1042. DOI: 10.1111/bjd.15706. View

20.

Krueger J, Fretzin S, Suarez-Farinas M, Haslett P, Phipps K, Cameron G . IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012; 130(1):145-54.e9. PMC: 3470466. DOI: 10.1016/j.jaci.2012.04.024. View